BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane.

被引：0
|
作者：
Moreno-Aspitia, A.
Hillman, D. W.
Wiesenfeld, M.
Hobday, T. J.
Rowland, K. M.
Northfelt, D. W.
Tenner, K. S.
Palmieri, F. M.
Perez, E. A.
机构：
[1] Mayo Clin, Jacksonville, FL 32224 USA
[2] Mayo Clin, Rochester, MN USA
[3] Oncol Associates, Cedar Rapids, IA USA
[4] Carle Canc Ctr, Urbana, IL USA
[5] Mayo Clin Scottsdale, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：22S / 22S
页数：1
相关论文
共 50 条
  • [21] A Phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC)
    Chen, E.
    Winquist, E.
    Agulnik, M.
    Chin, S.
    Pond, G.
    Cheiken, R.
    Francis, P.
    Petrenciuc, O.
    Siu, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 297 - 297
  • [22] Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer
    Wist, EA
    Sommer, HH
    Ostenstad, B
    Risberg, T
    Bremnes, Y
    Mjaaland, I
    ACTA ONCOLOGICA, 2004, 43 (02) : 186 - 189
  • [23] Phase II study of BAY 43-9006 (sorafenib) in patients with chemo-naive hormone refractory prostate cancer
    Akyol, F.
    Ozyigit, G.
    Selek, U.
    Onal, C.
    Karabulut, E.
    Ozen, H.
    EJC SUPPLEMENTS, 2005, 3 (02): : 248 - 249
  • [24] Phase II study of BAY 43-9006 using the randomized discontinuation design in patients with advanced refractory cancer.
    Ratain, MJ
    Stadler, W
    Smith, M
    Kindler, H
    O'Dwyer, P
    Flaherty, KT
    Kaye, S
    Xiong, H
    Eisen, T
    Patnaik, A
    Lee, RJ
    Lewis, J
    Schwartz, B
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6265S - 6266S
  • [25] Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer: An overview
    Andreopoulou E.
    Sparano J.A.
    Current Breast Cancer Reports, 2013, 5 (1) : 42 - 50
  • [26] Potential role of pemetrexed in metastatic breast cancer patients pretreated with anthracycline or taxane
    Zhou Li-Yan
    Shi Ye-Hui
    Jia Yong-Sheng
    Tong Zhong-Sheng
    慢性疾病与转化医学（英文）, 2015, 1 (01) : 27 - 28-29-30-31-32-33-34-35
  • [27] N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy
    Crozier, Jennifer A.
    Advani, Pooja P.
    LaPlant, Betsy
    Hobday, Timothy
    Jaslowski, Anthony J.
    Moreno-Aspitia, Alvaro
    Perez, Edith A.
    CLINICAL BREAST CANCER, 2016, 16 (01) : 23 - 30
  • [28] Prescription patterns for metastatic breast cancer patients previously treated with anthracycline and taxane: An assessment in a United States managed care database
    Harris, L. A.
    Yu, Y.
    Donato, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] A phase I study of BMS-247550 in combination with capecitabine in patients with metastatic breast cancer previously treated with a taxane and an anthracycline
    Thomas, E
    Bunnell, CA
    Vahdat, LT
    Schwartsberg, LS
    Gralow, JR
    Whitaker, LM
    Peck, R
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S83 - S83
  • [30] Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
    Vahdat, Linda T.
    Pruitt, Brian
    Fabian, Carol J.
    Rivera, Ragene R.
    Smith, David A.
    Tan-Chiu, Elizabeth
    Wright, Jonathan
    Tan, Antoinette R.
    DaCosta, Noshir A.
    Chuang, Ellen
    Smith, John
    O'Shaughnessy, Joyce
    Shuster, Dale E.
    Meneses, Nicole L.
    Chandrawansa, Kumari
    Fang, Fang
    Cole, Patricia E.
    Ashworth, Simon
    Blum, Joanne L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 2954 - 2961
12345